vs
FOSTER L B CO（FSTR）とTransMedics Group, Inc.（TMDX）の財務データ比較。上の社名をクリックして会社を切り替えられます
TransMedics Group, Inc.の直近四半期売上が大きい（$160.8M vs $160.4M、FOSTER L B COの約1.0倍）。TransMedics Group, Inc.の純利益率が高く（65.6% vs 1.5%、差は64.0%）。TransMedics Group, Inc.の前年同期比売上増加率が高い（32.2% vs 25.1%）。FOSTER L B COの直近四半期フリーキャッシュフローが多い（$19.8M vs $19.0M）。過去8四半期でTransMedics Group, Inc.の売上複合成長率が高い（28.8% vs 13.6%）
Foster L B Co.は米国に本拠を置く産業用製品メーカーで、工学設計されたアクセス製品、建設用部品、鉄道インフラ資材などを開発・生産・販売しています。主な顧客は北米を中心とする商業建設、交通、産業分野の企業です。
TransMedics Group, Inc.は臓器移植向けの革新的な医療技術を開発・販売する企業です。主力製品の臓器ケアシステムは輸送中のドナー臓器の生存性を維持し、心臓、肺、肝臓、腎臓移植の成功率向上に貢献し、北米、欧州、アジア太平洋地域の移植センターなどにサービスを提供しています。
FSTR vs TMDX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $160.4M | $160.8M |
| 純利益 | $2.4M | $105.4M |
| 粗利率 | 19.7% | 58.1% |
| 営業利益率 | 4.9% | 13.2% |
| 純利益率 | 1.5% | 65.6% |
| 売上前年比 | 25.1% | 32.2% |
| 純利益前年比 | 1098.3% | 1436.9% |
| EPS（希薄化後） | $0.22 | $2.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $160.4M | $160.8M | ||
| Q3 25 | $138.3M | $143.8M | ||
| Q2 25 | $143.6M | $157.4M | ||
| Q1 25 | $97.8M | $143.5M | ||
| Q4 24 | $128.2M | $121.6M | ||
| Q3 24 | $137.5M | $108.8M | ||
| Q2 24 | $140.8M | $114.3M | ||
| Q1 24 | $124.3M | $96.8M |
| Q4 25 | $2.4M | $105.4M | ||
| Q3 25 | $4.4M | $24.3M | ||
| Q2 25 | $2.9M | $34.9M | ||
| Q1 25 | $-2.1M | $25.7M | ||
| Q4 24 | $-242.0K | $6.9M | ||
| Q3 24 | $35.9M | $4.2M | ||
| Q2 24 | $2.8M | $12.2M | ||
| Q1 24 | $4.4M | $12.2M |
| Q4 25 | 19.7% | 58.1% | ||
| Q3 25 | 22.5% | 58.8% | ||
| Q2 25 | 21.5% | 61.4% | ||
| Q1 25 | 20.6% | 61.5% | ||
| Q4 24 | 22.3% | 59.2% | ||
| Q3 24 | 23.8% | 55.9% | ||
| Q2 24 | 21.7% | 60.6% | ||
| Q1 24 | 21.1% | 61.9% |
| Q4 25 | 4.9% | 13.2% | ||
| Q3 25 | 6.0% | 16.2% | ||
| Q2 25 | 5.3% | 23.2% | ||
| Q1 25 | -2.0% | 19.1% | ||
| Q4 24 | 2.4% | 7.1% | ||
| Q3 24 | 5.3% | 3.6% | ||
| Q2 24 | 3.2% | 10.9% | ||
| Q1 24 | 4.5% | 12.8% |
| Q4 25 | 1.5% | 65.6% | ||
| Q3 25 | 3.1% | 16.9% | ||
| Q2 25 | 2.0% | 22.2% | ||
| Q1 25 | -2.2% | 17.9% | ||
| Q4 24 | -0.2% | 5.6% | ||
| Q3 24 | 26.1% | 3.9% | ||
| Q2 24 | 2.0% | 10.7% | ||
| Q1 24 | 3.6% | 12.6% |
| Q4 25 | $0.22 | $2.59 | ||
| Q3 25 | $0.40 | $0.66 | ||
| Q2 25 | $0.27 | $0.92 | ||
| Q1 25 | $-0.20 | $0.70 | ||
| Q4 24 | $-0.04 | $0.19 | ||
| Q3 24 | $3.27 | $0.12 | ||
| Q2 24 | $0.26 | $0.35 | ||
| Q1 24 | $0.40 | $0.35 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $4.3M | — |
| 総負債低いほど良い | $42.6M | — |
| 株主資本純資産 | $175.3M | $473.1M |
| 総資産 | $330.4M | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.24× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $4.3M | — | ||
| Q3 25 | $3.4M | — | ||
| Q2 25 | $4.2M | — | ||
| Q1 25 | $2.6M | — | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $3.1M | $330.1M | ||
| Q2 24 | $4.0M | $362.8M | ||
| Q1 24 | $3.1M | $350.2M |
| Q4 25 | $42.6M | — | ||
| Q3 25 | $58.6M | — | ||
| Q2 25 | $81.4M | — | ||
| Q1 25 | $82.3M | — | ||
| Q4 24 | $46.8M | — | ||
| Q3 24 | $68.4M | — | ||
| Q2 24 | $87.0M | — | ||
| Q1 24 | $77.9M | — |
| Q4 25 | $175.3M | $473.1M | ||
| Q3 25 | $174.8M | $355.2M | ||
| Q2 25 | $174.4M | $318.1M | ||
| Q1 25 | $170.8M | $266.3M | ||
| Q4 24 | $178.3M | $228.6M | ||
| Q3 24 | $181.9M | $209.9M | ||
| Q2 24 | $147.1M | $189.9M | ||
| Q1 24 | $144.6M | $159.5M |
| Q4 25 | $330.4M | $1.1B | ||
| Q3 25 | $333.9M | $946.0M | ||
| Q2 25 | $349.9M | $890.5M | ||
| Q1 25 | $342.8M | $837.5M | ||
| Q4 24 | $334.6M | $804.1M | ||
| Q3 24 | $344.5M | $785.6M | ||
| Q2 24 | $333.3M | $758.6M | ||
| Q1 24 | $326.4M | $723.8M |
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.33× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 0.59× | — | ||
| Q1 24 | 0.54× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $22.2M | $34.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $19.8M | $19.0M |
| FCFマージンFCF / 売上 | 12.3% | 11.8% |
| 設備投資強度設備投資 / 売上 | 1.5% | 9.7% |
| キャッシュ転換率営業CF / 純利益 | 9.18× | 0.33× |
| 直近12ヶ月FCF直近4四半期 | $25.2M | $133.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $22.2M | $34.5M | ||
| Q3 25 | $29.2M | $69.6M | ||
| Q2 25 | $10.4M | $91.6M | ||
| Q1 25 | $-26.1M | $-2.9M | ||
| Q4 24 | $24.3M | $19.7M | ||
| Q3 24 | $24.7M | $6.9M | ||
| Q2 24 | $-5.0M | $25.7M | ||
| Q1 24 | $-21.4M | $-3.4M |
| Q4 25 | $19.8M | $19.0M | ||
| Q3 25 | $26.4M | $61.9M | ||
| Q2 25 | $7.7M | $82.5M | ||
| Q1 25 | $-28.7M | $-29.9M | ||
| Q4 24 | $22.3M | $6.1M | ||
| Q3 24 | $21.7M | $-41.3M | ||
| Q2 24 | $-7.0M | $2.0M | ||
| Q1 24 | $-24.2M | $-47.6M |
| Q4 25 | 12.3% | 11.8% | ||
| Q3 25 | 19.1% | 43.1% | ||
| Q2 25 | 5.4% | 52.4% | ||
| Q1 25 | -29.4% | -20.8% | ||
| Q4 24 | 17.4% | 5.0% | ||
| Q3 24 | 15.8% | -38.0% | ||
| Q2 24 | -5.0% | 1.7% | ||
| Q1 24 | -19.4% | -49.2% |
| Q4 25 | 1.5% | 9.7% | ||
| Q3 25 | 2.0% | 5.3% | ||
| Q2 25 | 1.9% | 5.8% | ||
| Q1 25 | 2.6% | 18.8% | ||
| Q4 24 | 1.5% | 11.2% | ||
| Q3 24 | 2.2% | 44.3% | ||
| Q2 24 | 1.5% | 20.8% | ||
| Q1 24 | 2.2% | 45.6% |
| Q4 25 | 9.18× | 0.33× | ||
| Q3 25 | 6.70× | 2.86× | ||
| Q2 25 | 3.61× | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | 0.69× | 1.63× | ||
| Q2 24 | -1.74× | 2.11× | ||
| Q1 24 | -4.83× | -0.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FSTR
| Rail Technologies And Services Segment | $98.0M | 61% |
| Over Time Output Method | $26.3M | 16% |
| Services | $19.4M | 12% |
| Rail Technologies Products | $10.0M | 6% |
| Over Time Input Method | $8.3M | 5% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
